Therefore, for patients with clinically highly suspected CML, it is necessary to screen for atypical BCR::ABL fusion genes in patients negative for common BCR::ABL fusion variants to gain a better understanding of the treatment of rare BCR::ABL fusion variants. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.